Core Insights - The year 2025 marks a significant milestone for China's innovative pharmaceutical industry, characterized by intense interactions between capital and industry, with BD transaction totals exceeding $130 billion, setting a historical record and surpassing 50% of the global market share [1][5] - The market has experienced a rollercoaster ride, with a resurgence in the first half of the year followed by a collective pullback in the third quarter, highlighting the importance of distinguishing between companies driven by solid fundamentals versus those reliant on market sentiment [3][10] - The industry is transitioning from "scale expansion" to "value realization," indicating a shift towards more sustainable growth and resilience in the face of external uncertainties [1][12] BD Transactions - In 2025, China saw explosive growth in license-out transactions, with over 100 deals totaling more than $110 billion, including 15 transactions with upfront payments exceeding $100 million [5][6] - Notable milestone BD transactions include a $12.5 billion deal between 3SBio and Pfizer, and a $114 billion strategic partnership between Innovent Biologics and Takeda, marking a shift in traditional licensing models [5][6] - The total value of license-out transactions reached $130 billion, a year-on-year increase of over 150%, underscoring China's emergence as a key player in global pharmaceutical innovation [5][6] Market Dynamics - The traditional pharmaceutical companies are adapting and showing resilience, with firms like Hengrui Medicine and 3SBio successfully navigating the transition from generics to innovative drugs [4][10] - The industry is expected to continue its upward trajectory, supported by increased R&D investments, a growing number of clinical trials, and a dual payment system that enhances patient access to innovative therapies [10][11] - The anticipated "data validation year" in 2026 will see more Chinese innovative pipelines entering global clinical development, influencing market expectations for Chinese innovation [10][11] Future Outlook - The innovative pharmaceutical sector is poised for a more solid and resilient future, with a focus on delivering effective treatment solutions for patients and contributing to the global pharmaceutical landscape [12][13] - The ongoing demand for innovative assets from multinational corporations (MNCs) is expected to rise, driven by patent expirations and declining R&D efficiency, leading to a strategic focus on "in China for global" initiatives [6][7] - The industry is entering a new era characterized by value-driven growth, where the emphasis will be on the contribution of products to revenue rather than mere availability [7][9]

Investment Rating - The report does not explicitly state an investment rating for the interleukin industry Core Insights - The interleukin family consists of various cytokines that play significant roles in immune regulation, inflammation, and cancer, with many related drugs and clinical pipelines in development [4][5] - The IL-12 and IL-23 cytokines are crucial in immune modulation and have become important therapeutic targets for autoimmune diseases such as psoriasis and Crohn's disease [9][10] - The market for IL-4Rα drugs in allergic diseases is expanding, with two main drugs approved in China for treating allergic asthma and other conditions [16] - IL-1β inhibitors are gaining traction in gout treatment, with a notable increase in patient numbers projected for high uric acid levels and gout by 2030 [23][25] - Artificial intelligence is enhancing drug development processes across various stages, significantly reducing the time required for drug discovery and optimization [31][32] Summary by Sections Interleukin Family Overview - The interleukin family includes multiple members categorized into several groups, each with distinct roles in immune response and disease [3][4] - Key interleukins such as IL-1, IL-2, IL-6, IL-10, and IL-17 are involved in autoimmune and inflammatory diseases, with existing drugs and clinical pipelines targeting these cytokines [5] Market Status of IL-12/IL-23 - Several drugs targeting IL-12 and IL-23 have been approved for treating autoimmune diseases, with notable examples including Ustekinumab and Guselkumab [8][10] - The first fully human monoclonal antibody targeting IL-12/IL-23, Iroquois, is set to launch in 2025 for moderate to severe plaque psoriasis [10] IL-4 in Allergic Diseases - Two IL-4Rα drugs have been approved in China for allergic diseases, with Dupilumab included in the national medical insurance list [16] - The report outlines ongoing clinical trials for additional IL-4Rα therapies targeting various allergic conditions [17] IL-1β Inhibitors in Gout Treatment - The report highlights the increasing prevalence of high uric acid and gout, with projections indicating significant growth in patient numbers by 2030 [21][23] - The first IL-1β monoclonal antibody, Canakinumab, has been approved for gout treatment, with a projected global sales figure of $1.5 billion by 2024 [25] Role of Artificial Intelligence in Drug Development - AI is transforming drug discovery by streamlining processes and improving efficiency, reducing the time for lead compound optimization from approximately 65 months to 30 months [32] - The integration of AI in drug development enhances the accuracy of personalized medicine and accelerates the identification of effective drug candidates [31][32]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月31日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 www.grandall.com.cn 中国江苏省南京市汉中门大街 3 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月31日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-2 ...

Group 1 - The Hong Kong innovative drug market is returning to a bull market in 2025, driven by a significant BD deal worth $4.8 billion between 3SBio and Pfizer, with the Hang Seng Healthcare Index rising by 102.76% to a peak of 4721.41 points by September [1] - In 2025, the Hong Kong IPO market for new stocks ranked first globally, raising over 280 billion HKD, nearly three times the amount raised in the previous year, marking a new high in four years [1] - A total of 27 healthcare/biotech companies successfully went public in Hong Kong this year, with nearly 10 more companies submitting prospectuses in December, and about 300 companies still waiting in line, with one-third being health-related [1] Group 2 - The top five companies by IPO fundraising in 2025 include CATL with 41.006 billion HKD, Zijin Mining International with 28.732 billion HKD, SANY Heavy Industry with 15.349 billion HKD, Seres with 14.283 billion HKD, and Heng Rui Medicine with 11.374 billion HKD [2] - The performance of newly listed healthcare companies has been remarkable, with some experiencing significant stock price increases, such as Yaojie Ankang-B with a 773.76% increase and Xuanzhu Biotechnology-B with a 507.76% increase [3] Group 3 - The strong performance of the Hong Kong pharmaceutical sector is attributed to policy incentives and breakthroughs in innovation, marking a critical year for the Chinese pharmaceutical industry transitioning from "innovation awakening" to "value realization" [5] - The 2025 domestic pharmaceutical R&D policy focuses on "full-chain support for innovation and multi-level value assurance," significantly enhancing the market's expectations for growth in the innovative drug sector [5] Group 4 - The Hong Kong stock market has seen a significant increase in trading activity, with the total market capitalization reaching 48 trillion HKD, a 41% increase from the previous year, and the average daily trading volume rising by 95% to 255.8 billion HKD [7] - Southbound capital has become a crucial source of liquidity for the Hong Kong market, with a net purchase of 1.4 trillion HKD in 2025, indicating a strong interest in the pharmaceutical sector [7] Group 5 - The new IPO distribution mechanism implemented on August 4, 2025, has improved pricing efficiency and market stability, resulting in a decrease in the IPO failure rate to 28.83% compared to 32%-34% in previous years [8][9] - The innovative drug bull market has led to a lower IPO failure rate of approximately 17% for healthcare companies, with over 35% of new stocks experiencing first-day gains exceeding 100% [9] Group 6 - Despite the overall enthusiasm for the pharmaceutical sector, market sentiment shifted in December, with three healthcare IPOs experiencing significant first-day declines, indicating that investors are becoming more selective based on fundamentals [10] - Companies like Mingji Hospital and Hansi Aitai-B faced substantial first-day drops despite high oversubscription rates, while companies with stronger fundamentals, such as Yinxin Intelligent, achieved significant first-day gains [10]

江蘇恒瑞醫藥股份有限公司 章 程 | 目錄 | | --- | | 第一章 | 總則 | 2 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 3 | | 第三章 | 股份 | 4 | | 第一節 | 股份發行 | 4 | | 第二節 | 股份增減和回購 | 5 | | 第三節 | 股份轉讓 | 6 | | 第四章 | 股東和股東會 | 8 | | 第一節 | 股東 | 8 | | 第二節 | 控股股東和實際控制人 | 11 | | 第三節 | 股東會的一般規定 | 12 | | 第四節 | 股東會的召集 | 15 | | 第五節 | 股東會的提案與通知 | 16 | | 第六節 | 股東會的召開 | 18 | | 第七節 | 股東會的表決和決議 | 22 | | 第五章 | 董事會 | 27 | | 第一節 | 董事的一般規定 | 27 | | 第二節 | 董事會 | 32 | | 第三節 | 獨立董事 | 35 | | 第四節 | 董事會專門委員會 | 39 | | 第六章 | 高級管理人員 | 41 | | 第七章 | 財務會計制度、利潤分配和審計 | 43 | | 第一節 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 有關決議案的進一步詳情載於本公司日期為2025年12月10日的股東會通告（「該通 告」）及同日的通函（「通函」）。 除非文義另有所指，否則本公告所用詞彙與通函所界定者具有相同涵義。 截至股東會記錄日期，(i)本公司已發行股份（「股份」）總數為6,637,199,874股，包 含258,197,600股H股及6,379,002,274股A股；及(ii)6,633,460,924股股份的持有人 （或授權代表）有權出席股東會並於會上就提呈的決議案投票。用於計算出席股東 會的股份總數不包括本公司已回購並於股票回購賬戶持作庫存股份的3,738,950股 A股。本公司於股東會中並未就上述股份行使表決權。此外，概無本公司已購回 而待註銷的股份。 據本公司所知、所悉及所信，概無股東須根據香港上市規則的規定，於股東會上 就所提呈的決議案放棄投票。此外，概無任何一方於通函中表示有意就股東會上 提呈的決議案投反對票或放棄投票， ...

展望2026年，德勤预测，在目前超过300宗上市申请个案的名单支持下，2026年全年，香港新股市场将 有约160只新股融资不少于3000亿港元。预计其中将有7只新股，每只最少融资100亿港元，其中包括内 地龙头企业。除了有大量"A+H"股上市申请人外，科技、传媒及电信、医疗及医药、消费、国际公司， 以及在美上市的中概股的上市项目也将成为市场关注的焦点。 截至12月31日，今年共有117家新股登陆港股市场，较去年同期增加47家；合计募资规模2856.93亿港 元，超过2023年（463亿港元）及2024年（881.47亿港元）IPO募资额的总和，较去年同期增长 224.11%。其中，宁德时代募资额居榜首，贡献410亿港元。 | #新浪财经2025年终盘点# | | --- | | 点2025年 | | 港股前十大IPO | | 宁德时代 / 3750.HK 实际募资总额(百万港元) | | +16.43% 41,005.72 | | 紫金黄金国际 / 2259.HK | | #+68.46% 28,731.88 | | 三一重工 / 6031.HK | | +2.82% 15,349.09 | | 寒力斯 / ...

江苏恒瑞医药股份有限公司 章 程 | 第二章 | 经营宗旨和范围 | 3 | | --- | --- | --- | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东 | 7 | | 第二节 | 控股股东和实际控制人 10 | | | 第三节 | 股东会的一般规定 | 11 | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 14 | | | 第六节 | 股东会的召开 | 15 | | 第七节 | 股东会的表决和决议 18 | | | 第五章 | 董事会 | 22 | | 第一节 | 董事的一般规定 | 22 | | 第二节 | 董事会 | 25 | | 第三节 | 独立董事 | 28 | | 第四节 | 董事会专门委员会 | 30 | | | 第六章高级管理人员 | 32 | | 第七章 | 财务会计制度、利润分配和审计 33 | | | 第一节 | 财务会计制度 | 33 | | 第二节 | 内部审计 | 3 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-213 江苏恒瑞医药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五) 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事11人，出席11人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书出席会议；公司高管列席会议。 二、 议案审议情况 | 1、出席会议的股东和代理人人数 | 3,521 | | --- | --- | | 股股东人数 其中：A | 3,520 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 3,761,447,926 | | 股股东持有股份总数 其中：A | 3,612,743,654 | | 境外上市外资股股东持有股份总数（H 股） | 148,704,272 | | 3、出 ...